<DOC>
	<DOCNO>NCT01160666</DOCNO>
	<brief_summary>Sjögren 's syndrome ( SS ) systemic autoimmune disease characterize increase BAFF ( BLyS ) level result B cell hyperactivity . B cell involve pathogenesis SS systemic glandular feature , B cell downregulation may lead decrease disease activity . Moreover , pathogenesis SS close Systemic lupus erythematosus , Belimumab proven effective .</brief_summary>
	<brief_title>Efficacy Safety Belimumab Subjects With Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>Sjögren 's syndrome ( SS ) systemic autoimmune disease characterize increase BAFF ( BLyS ) level result B cell hyperactivity . B cell involve pathogenesis SS systemic glandular feature , B cell downregulation may lead decrease disease activity . Moreover , pathogenesis SS close Systemic lupus erythematosus , Belimumab proven effective . This phase II open-label study 2 main objective : - To evaluate proof concept efficacy belimumab subject SS - To evaluate safety tolerability belimumab subject SS Belimumab administer ( 10mg/kg D0 D14 D28 every 28 day 24 week , extension 48 week responder ) patient</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Have diagnosis primary SS accord updated American European Consensus Group Criteria . In addition , patient must always positive antiSSA antiSSB antibody Have presence , screen , Systemic involvement ( polysynovitis , skin , renal , lung , CNS involvement , peripheral neuropathy , vasculitis , autoimmune cytopenia , define Annex 1 ) persistent ( 2 month ) parotid , submandibular lachrymal gland swell 2 cm OR Objective sicca ( positive oral and/or ocular test report American European Consensus Group Criteria ) least one among follow biological feature serum B lymphocyte activation : increase IgG level increase free light chain level immunoglobulin ( accord central laboratory range ) increase serum beta2microglobulin level decrease C4 level ( C4 level inferior central laboratory range ) monoclonal gammapathy cryoglobulinemia OR SS recent onset , i.e. , less 5 year duration symptom , associate : oral ocular dryness fatigue musculoskeletal pain ( i.e , 3 criterion response report page ( ixx ) , characterize VAS score 50/100 3 field . 1 . Any BLyStargeted ( BLySreceptor fusion protein [ BR3 ] , TACI Fc , belimumab ) time . 2 . Any follow within 364 day Day 0 : Bcell target therapy ( eg , rituximab , antiCD20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alemtuzumab ] A biologic investigational agent B cell target therapy ( eg , abetimus sodium , anti CD40L antibody [ BG9588/ IDEC 131 ] ) . 4 Intravenous oral cyclophosphamide within 180 day Day 0 . 5 Any follow within 90 day Day 0 : AntiTNF therapy Interleukin1 receptor antagonist Abatacept Interleukin6 receptor antagonist Intravenous immunoglobulin Prednisone &gt; 100 mg/day Plasmapheresis . 9 Very severe SS disease . 10 Major organ hematopoietic stem cell/marrow transplant . 11 Unstable uncontrolled acute chronic disease due SS 13 History malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . 14 Required management acute chronic infection , follow : Currently suppressive therapy chronic infection Hospitalization treatment infection within 60 day Day 0 . Use parenteral ( IV IM ) antibiotics 16 Historically screen positive test HIV antibody , hepatitis C virus antibody , , hepatitis B surface antigen ( HbsAg ) ( without positive serum HBV DNA ) , antiHBcAg positivity ( without antiHbsAg positivity ) . 17 Grade 3 great laboratory abnormality base protocol toxicity scale except follow allow : Stable Grade 3 prothrombin time ( PT ) secondary warfarin treatment . Stable Grade 3/4 proteinuria ( ≤ 6 g/24 hour equivalent spot urine protein creatinine ratio allow ) . ( mention early Exclusion # 8 ) Stable Grade 3 neutropenia stable Grade 3 white blood cell count .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Belimumab</keyword>
	<keyword>Sjögren 's syndrome</keyword>
	<keyword>Sjögren disease</keyword>
</DOC>